Nath A - Search Results

1

Blocking cancer-fibroblast mutualism inhibits proliferation of endocrine therapy resistant breast cancer.

Griffiths JI, Chi F, Farmaki E, Medina EF, Cosgrove PA, Karimi KL, Chen J, Grolmusz VK, Adler FR, Khan QJ, Nath A, Chang JT, Bild AH. Griffiths JI, et al. Among authors: nath a. Mol Syst Biol. 2025 May 8. doi: 10.1038/s44320-025-00104-6. Online ahead of print. Mol Syst Biol. 2025. PMID: 40341770 Free article.

2

Predicting clinical response to everolimus in ER+ breast cancers using machine-learning.

Nath A, Cosgrove PA, Chang JT, Bild AH. Nath A, et al. Front Mol Biosci. 2022 Oct 11;9:981962. doi: 10.3389/fmolb.2022.981962. eCollection 2022. Front Mol Biosci. 2022. PMID: 36304922 Free PMC article.

3

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.

Farmaki E, Nath A, Emond R, Karimi KL, Grolmusz VK, Cosgrove PA, Bild AH. Farmaki E, et al. Among authors: nath a. Elife. 2023 Sep 29;12:e85898. doi: 10.7554/eLife.85898. Elife. 2023. PMID: 37772709 Free PMC article.

4

Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.

Chi F, Griffiths JI, Nath A, Bild AH. Chi F, et al. Among authors: nath a. Breast Cancer Res. 2024 Mar 29;26(1):54. doi: 10.1186/s13058-024-01808-7. Breast Cancer Res. 2024. PMID: 38553760 Free PMC article.

5

A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind.

Emond R, West J, Grolmusz V, Cosgrove P, Nath A, Anderson ARA, Bild AH. Emond R, et al. Among authors: nath a. bioRxiv [Preprint]. 2024 Sep 6:2024.09.03.611032. doi: 10.1101/2024.09.03.611032. bioRxiv. 2024. PMID: 39282402 Free PMC article. Preprint.

6

A machine learning framework for scRNA-seq UMI threshold optimization and accurate classification of cell types.

Bishara I, Chen J, Griffiths JI, Bild AH, Nath A. Bishara I, et al. Among authors: nath a. Front Genet. 2022 Nov 25;13:982019. doi: 10.3389/fgene.2022.982019. eCollection 2022. Front Genet. 2022. PMID: 36506328 Free PMC article.

7

Unraveling phenotypic plasticity and evolution in small cell lung cancer.

Nath A. Nath A. Cell Syst. 2022 Sep 21;13(9):687-689. doi: 10.1016/j.cels.2022.08.005. Cell Syst. 2022. PMID: 36137510 Free article.

8

Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overview.

Garg P, Singhal G, Pareek S, Kulkarni P, Horne D, Nath A, Salgia R, Singhal SS. Garg P, et al. Among authors: nath a. Biochim Biophys Acta Rev Cancer. 2025 Feb;1880(1):189233. doi: 10.1016/j.bbcan.2024.189233. Epub 2024 Dec 3. Biochim Biophys Acta Rev Cancer. 2025. PMID: 39638158 Free article. Review.

9

Clinical spectrum of lung cancer across hospitals under the National Cancer Registry Programme in India: Challenges and opportunities.

Kumar S, Nath A, Sudarshan KL, Ramamoorthy T, Sakia J, Kumar N, Deo SV, Jain D, Malik PS, Mathur P. Kumar S, et al. Among authors: nath a. Lung India. 2025 Jul 1;42(4):283-290. doi: 10.4103/lungindia.lungindia_569_24. Epub 2025 Jun 27. Lung India. 2025. PMID: 40569394 Free article.

10

A novel frameshift mutation in Phosphoinositide 3-kinase regulatory subunit 1 ( PIK3R1 ) causes immunodeficiency and Amyotrophic Lateral Sclerosis (ALS).

Calco B, Sweeney CL, Steiner J, Wang T, Markowitz TE, Paul S, Palicha B, Dinges S, Yoo K, Henderson L, McDonald V, De Ravin SS, Greenberg B, Zerbe CS, Notarangelo LD, Holland SM, Nath A, Safavi F. Calco B, et al. Among authors: nath a. bioRxiv [Preprint]. 2025 May 28:2025.05.23.655625. doi: 10.1101/2025.05.23.655625. bioRxiv. 2025. PMID: 40568112 Free PMC article. Preprint.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,454 results

Search Page

Filters